Cargando…

Development of mouse models with restricted HLA-B*57:01 presentation for the study of flucloxacillin-driven T-cell activation and tolerance in liver injury

BACKGROUND: Flucloxacillin (FLX)-induced liver injury is immune-mediated and highly associated to HLA-B*57:01 expression. Host factors leading to drug-induced liver injury are not yet well understood. OBJECTIVE: Characterize in vivo immune mechanisms determining the development of CD8(+) T cells rea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ananthula, Suryatheja, Sivakumar, Kirthiram Krishnaveni, Cardone, Marco, Su, Shan, Roderiquez, Gregory, Abuzeineh, Hanan, Kleiner, David E., Norcross, Michael A., Puig, Montserrat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10524621/ https://www.ncbi.nlm.nih.gov/pubmed/37030592 http://dx.doi.org/10.1016/j.jaci.2023.03.029

Ejemplares similares

Alterations in the HLA-B*57:01 Immunopeptidome by Flucloxacillin and Immunogenicity of Drug-Haptenated Peptides
por: Puig, Montserrat, et al.
Publicado: (2021)

Transgenic murine models for the study of drug hypersensitivity reactions linked to HLA-I molecules
por: Puig, Montserrat, et al.
Publicado: (2023)

Identification of flucloxacillin-modified hepatocellular proteins: implications in flucloxacillin-induced liver injury
por: Ali, Serat-E, et al.
Publicado: (2023)

Abacavir inhibits but does not cause self-reactivity to HLA-B*57:01-restricted EBV specific T cell receptors
por: Sooda, Anuradha, et al.
Publicado: (2022)

Control of Adaptive Immune Responses by Staphylococcus aureus through IL-10, PD-L1, and TLR2
por: Wang, Jinhai, et al.
Publicado: (2012)

Flucloxacillin and paracetamol induced pyroglutamic acidosis
por: Zand Irani, Anis, et al.
Publicado: (2021)

HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects
por: Small, Catherine Butkus, et al.
Publicado: (2017)

Peptide-Dependent Recognition of HLA-B*57:01 by KIR3DS1
por: O'Connor, Geraldine M., et al.
Publicado: (2015)

Oral Flucloxacillin for Staphylococcal Osteomyelitis: Obsolete or Underused?
por: Tevell, Staffan, et al.
Publicado: (2020)

Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01
por: Cascella, R, et al.
Publicado: (2015)

Influence of Glycosylation Inhibition on the Binding of KIR3DL1 to HLA-B*57:01
por: Salzberger, Wilhelm, et al.
Publicado: (2015)

Unravelling the Proteomics of HLA-B*57:01(+) Antigen Presenting Cells during Abacavir Medication
por: Haukamp, Funmilola Josephine, et al.
Publicado: (2022)

An Accelerated Release Study to Evaluate Long-Acting Contraceptive Levonorgestrel-Containing in Situ Forming Depot Systems
por: Janagam, Dileep R., et al.
Publicado: (2016)

Oral flucloxacillin and phenoxymethylpenicillin versus flucloxacillin alone for the emergency department outpatient treatment of cellulitis: study protocol for a randomised controlled trial
por: Quirke, Michael, et al.
Publicado: (2013)

HLA-E*01:01 + HLA-E*01:01 genotype confers less susceptibility to COVID-19, while HLA-E*01:03 + HLA-E*01:03 genotype is associated with more severe disease
por: Hosseini, Ehteramolsadat, et al.
Publicado: (2023)

Chemical modification of the 6'-amino cyclopropyl of abacavir eliminates HLA-B*57:01-restricted CD8+ T-cell activation without loss of antiviral activity
por: Alhaidari, Mohammad, et al.
Publicado: (2014)

Bile Nephropathy in Flucloxacillin-Induced Cholestatic Liver Dysfunction
por: Alnasrallah, Basil, et al.
Publicado: (2016)

Broad-spectrum azoles and flucloxacillin: a dangerous match
por: Vangheluwe, Tine, et al.
Publicado: (2021)

High unbound flucloxacillin fraction in critically ill patients
por: Wallenburg, Eveline, et al.
Publicado: (2021)

Concomitant Treatment with Voriconazole and Flucloxacillin: A Combination to Avoid
por: Van Daele, Ruth, et al.
Publicado: (2021)

2533. Cerebrospinal Fluid Penetration of Cefazolin and Flucloxacillin in Children
por: Boast, Alison, et al.
Publicado: (2023)

Acyclovir Has Low but Detectable Influence on HLA-B*57:01 Specificity without Inducing Hypersensitivity
por: Metushi, Imir G., et al.
Publicado: (2015)

HLA-B*57:01 allele prevalence in treatment-Naïve HIV-infected patients from Colombia
por: Martínez Buitrago, Ernesto, et al.
Publicado: (2019)

Prevalence of human leukocyte antigen HLA-B*57:01 in individuals with HIV in West and Central Africa
por: Kolou, Malewe, et al.
Publicado: (2021)

CCM no. 80-01: no. 57
Publicado: (1980)

Comparison of Methods for In-House Screening of HLA-B*57:01 to Prevent Abacavir Hypersensitivity in HIV-1 Care
por: De Spiegelaere, Ward, et al.
Publicado: (2015)

Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study
por: Van Den Driessche, George, et al.
Publicado: (2017)

Intravenous flucloxacillin treatment is associated with a high incidence of hypokalaemia
por: van der Heijden, Charlotte D.C.C., et al.
Publicado: (2019)

Identification of Functional HLA-A*01:01–Restricted Epstein-Barr Latent Membrane Protein 2–Specific T-Cell Receptors( )
por: Huisman, Wesley, et al.
Publicado: (2020)

HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, Age and Sex Are Associated With Severity of Japanese COVID-19 With Respiratory Failure
por: Khor, Seik-Soon, et al.
Publicado: (2021)

Identification of HLA‐A*11:01‐restricted Mycobacterium tuberculosis CD8(+) T cell epitopes
por: Liu, Su‐Dong, et al.
Publicado: (2016)

Rapid Multiplex Genotyping of 20 HLA-A(*)02:01 Restricted Minor Histocompatibility Antigens
por: Romaniuk, Dmitrii S., et al.
Publicado: (2019)

Improving turnaround times for HLA-B*27 and HLA-B*57:01 gene testing: a Barts Health NHS Trust quality improvement project
por: White, Emma, et al.
Publicado: (2021)

LBA73 The ORF1ab of SARS-CoV-2 encodes an immunodominant epitope restricted by HLA-A*01:01
por: Kvistborg, P., et al.
Publicado: (2020)

Characterization of Flucloxacillin-specific CD8+ T-cells in a mouse model
por: Nattrass, Ryan, et al.
Publicado: (2014)

Clinical factors predicting drug-induced liver injury due to flucloxacillin
por: Lindh, Mikaela, et al.
Publicado: (2018)

Paclitaxel, Imatinib and 5-Fluorouracil Increase the Unbound Fraction of Flucloxacillin In Vitro
por: Stolte, Maximilian, et al.
Publicado: (2020)

Oral Flucloxacillin for Treating Osteomyelitis: A Narrative Review of Clinical Practice
por: Preiss, Helga, et al.
Publicado: (2020)

Flucloxacillin/paracetamol: High-anion gap metabolic acidosis : case report
Publicado: (2021)

Human Leukocyte Antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 Present Complementary Peptide Repertoires
por: Scholz, Erika Margaret, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_robgcjme8c41ars8e7ggjtg0ic